CXCL10, CXCL11 and CCL18 predict asthma and sensitisation
As some of the chemokines indeed associated with the development of
asthma and sensitisation later in childhood, we tested the ability of
the chemokine levels to predict asthma (Figure 4A) and sensitisation
(Figure 4B) later in childhood and adolescence using binomial logistic
regression models.
Asthma: Having higher CXCL11 levels at birth constituted lower
odds of being asthmatic at age 16 (OR=0.4, 95% CI 0.2-0.8, p=0.012).
Furthermore, higher CCL18 levels at 8 years of age markedly increased
the odds of being asthmatic at ages 8 (OR=3.8, 95% CI 1.5-9.8, p=0.006)
and 16 years (OR=5.3, 95% CI 1.7-16.1, p=0.003).
Sensitisation: Presenting with elevated CCL18 levels at age 8,
posed a three times or higher odds ratio for developing sensitisation at
ages 8 (OR=3.3, 95% CI 1.5-7.1, p=0.002), 11 (OR=3.0, 95% CI 1.3-6.7,
p=0.008) and 16 years of age, (OR=4.2, 95% CI 1.7-10.5, p=0.002). In
contrast, having high levels of CXCL10 at age 8 seemed protective
against becoming sensitised at age 11 (OR=0.4, 95% CI 0.2-0.8,
p=0.012).